题目内容
ENT Entertainment Co (ENT) is a large, diversified entertainment business based in Teeland. The company’s objective is the maximisation of shareholder wealth for its family owners. It has four divisions:
1. Restaurants
2. Cafes
3. Bars
4. Dance clubs
Recently, ENT’s board have identified that there are problems in managing such a diversified company. They have employed consultants who have recommended that they should perform. a Boston Consulting Group (BCG) analysis to understand whether they have the right mix of businesses. The chief executive officer (CEO) has questioned whether using this analysis is helpful in managing the group’s performance. A business analyst has prepared information on each division in the table below.
In Teeland, the economy is generally growing at about 2% per annum. The restaurant, cafe and bar sectors are all highly fragmented with many small operators. Consequently, a market share of more than 3·0% is considered large as that is comparable to the share of the largest operators in each sector. There are fewer small late night dance club operators and the market leader currently holds a 15·0% market share. There have not been many new developments within the divisions except for a new wine bar format launched by the bars division which has surprised the board by its success.
Each of the division’s performance is measured by economic value-added (EVA？). The divisional managers have a remuneration package that is made up in two equal parts by a salary set according to industry norms and a bonus element which is based on achieving the cost budget numbers set by the company board. The chairman of the board has been examining the consistency of the overall objective of the business, the divisional performance measure and the remuneration packages at divisional level. He has expressed the worry that these are not properly aligned and that this might lead to dysfunctional behaviour by the divisional management.
Required:
(a) Perform. a BCG analysis of ENT’s business and use this to evaluate the company’s performance. (7 marks)
(b) Critically evaluate this BCG analysis as a performance management system at ENT. (7 marks)
(c) Evaluate the divisional managers’ remuneration package in light of the divisional performance system and your BCG analysis. (6 marks)
查看答案
搜索结果不匹配？点我反馈
更多问题
PLX Refinery Co is a large oil refinery business in Kayland. Kayland is a developing country with a large and growing oil exploration and production business which supplies PLX with crude oil. Currently, the refinery has the capacity to process 200,000 barrels of crude oil per day and makes profits of $146m per year. It employs about 2,000 staff and contractors. The staff are paid $60,000 each per year on average (about twice the national average pay in Kayland).
The government of Kayland has been focused on delivering rapid economic growth over the last 15 years. However, there are increasing signs that the environment is paying a large price for this growth with public health suffering. There is now a growing environmental pressure group, Green Kayland (GK), which is organising protests against the companies that they see as being the major polluters.
Kayland’s government wishes to react to the concerns of the public and the pressure groups. It has requested that companies involved in heavy industry contribute to a general improvement in the treatment of the environment in Kayland.
As a major participant in the oil industry with ties to the nationalised oil exploration company (Kayex), PLX believes it will be strategically important to be at the forefront of environmental developments. It is working with other companies in the oil industry to improve environmental reporting since there is a belief that this will lead to improved public perception and economic efficiency of the industry. PLX has had a fairly good compliance record in Kayland, with only two major fines being levied in the last eight years for safety breaches and river pollution ($1m each).
The existing information systems within PLX focus on financial performance. They support financial reporting obligations and allow monitoring of key performance metrics such as earnings per share and operating margins. Recent publications on environmental accounting have suggested there are a number of techniques (such as input/output analysis, activity-based costing (ABC) and a lifecycle view) that may be relevant in implementing improvements to these systems.
PLX is considering a major capital expenditure programme to enhance capacity, safety and efficiency at the refinery. This will involve demolishing certain older sections of the refinery and building on newly acquired land adjacent to the site. Overall, the refinery will increase its land area by 20%.
Part of the refinery extension will also manufacture a new plastic, Kayplas. Kayplas is expected to have a limited market life of five years after which it will be replaced by Kayplas2. The refinery accounting team have forecast the following data associated with this product and calculated PLX’s traditional performance measure of product profit for the new product:
All figures are $m’s
Subsequently, the following environmental costs have been identified from PLX’s general overheads as associated with Kayplas production.
Additionally, other costs associated with closing down and recycling the equipment in Kayplas production are estimated at $18m in 2016.
The board wishes to consider how it can contribute to the oil industry’s performance in environmental accounting, how it can implement the changes that this might require and how these changes will benefit the company.
Required:
(a) Discuss different cost categories that would aid transparency in environmental reporting both internally and externally at PLX. (4 marks)
(b) Explain and evaluate how the three environmental accounting techniques mentioned can assist in managing the environmental and strategic performance of PLX. (9 marks)
(c) Evaluate the costing approach used for Kayplas’s performance compared to a lifecycle costing approach, performing appropriate calculations. (7 marks)
Pharmaceutical Technologies Co (PT) is a developer and manufacturer of medical drugs in Beeland. It is one of the 100 largest listed companies on the national stock exchange. The company focuses on buying prospective drugs that have shown initial promise in testing from small bio-engineering companies. PT then leads these through three regulatory stages to launch in the general medical market. The three stages are:
1. to confirm the safety of the drug (does it harm humans？), in small scale trials;
2. to test the efficacy of the product (does it help cure？), again in small scale trials; and
3. finally, large scale trials to definitively decide on the safety and efficacy of the product.
The drugs are then marketed through the company’s large sales force to health care providers and end users (patients). The health care providers are paid by either health insurance companies or the national government dependent on the financial status of the patient.
The Beeland Drug Regulator (BDR) oversees this testing process and makes the final judgement about whether a product can be sold in the country.
Its objectives are to protect, promote and improve public health by ensuring that:
– medicines have an acceptable balance of benefit and risk;
– the users of these medicines understand this risk-benefit profile; and
– new beneficial product development is encouraged.
The regulator is governed by a board of trustees appointed by the government. It is funded directly by the government and also through fees charged to drug companies when granting licences to sell their products in Beeland.
PT has used share price and earnings per share as its principal measures of performance to date. However, the share price has underperformed the market and the health sector in the last two years. The chief executive officer (CEO) has identified that these measures are too narrow and is considering implementing a balanced scorecard approach to address this problem.
A working group has drawn up a suggested balanced scorecard. It began by identifying the objectives from the board’s medium term strategy:
– Create shareholder value by bringing commercially viable drugs to market
– Improve the efficiency of drug development
– Increase shareholder value by innovation in the drug approval process
The working group then considered the stakeholder perspectives:
– Shareholders want a competitive return on their investment
– Purchasers (governments, insurers and patients) want to pay a reasonable price for the drugs
– Regulators want an efficient process for the validation of drugs
– Doctors want safe and effective drug products
– Patients want to be cured
Finally, this leads to the proposed scorecard of performance measures:
– Financial – share price and earnings per share
– Customer – number of patients using PT products
– Internal business process – exceed industry-standard on design and testing; time to regulatory approval of a product
– Learning and growth – training days undertaken by staff; time to market of new product; percentage of drugs bought by PT that gain final approval.
The balanced scorecard now needs to be reviewed to ensure that it will address the company’s objectives and the issues that it faces in its business environment.
Required:
(a) Describe how the implementation of a balanced scorecard delivers a range of performance measures aligned with the corporate strategy. (4 marks)
(b) Evaluate the performance measures proposed for PT’s balanced scorecard. (10 marks)
(c) Identify and analyse the influence of four different external stakeholders on the regulator (BDR). (6 marks)
(d) Using your answer from part (c), describe how the application of the balanced scorecard approach at BDR would differ from the approach within PT. (7 marks)
寄生在人体淋巴系统的寄生虫是
属于浆细胞病的是
微信支付 
支付宝支付